Is BioInvent International AB (publ) (BOVNF) a Buy, Sell, or Hold?
OTC : BOVNF
BioInvent International AB (publ)
$3.2886 USD
$0 (0.0%)
- Volume
- 908
- Average Volume
- 777
- Market Capitalization
- $216.4M
- P/E Ratio
- -4.54
- Dividend Yield
- 0.00%
- Price Target
- Year High
- $4.70
- Year Low
- $3.29
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $5.32
Company Overview
OTC
Martin Welschof
Biotechnology
Healthcare
BOVNF
109
SE
USD
Liquidity Metrics
0.01
5.32
5.20
3.75
0.00
Sales & Valuation
$225.93M
6.98
3.47
-5.72
-4.03
Profitability
-$5.07
-$332.02M
-153.98%
-153.78%
-53.88%
-62.71%
P/E Metrics
-4.54
-0.24
-0.24
Analyst Price Target & Rating
0/5
0 Analysts
%
Financial Health Scores
12.06
2/9
$410.58M
$534.96M
$95.85M
-$344.46M
Key Metrics (TTM)
$1.17B
5.36
-3.57
5.32
-53.88%
-78.78%
-22.09%
-17.52%
63 days
Company Executives
| Name | Title |
|---|---|
| Ingrid Teige | Head of Preclinical Research |
| Kristoffer Rudenholm Hansson | Senior Vice President of Technical Operations |
| Sylvie Ryckebusch | Chief Business Officer |
| Andres McAllister | Chief Medical Officer |
| Stefan Ericsson | Chief Financial Officer |
| Ashley R. Robinson | Senior VP of Strategy & Finance |
| Björn Frendéus | Chief Scientific Officer |
| Ingunn Munch Lindvig | Senior Vice President of Regulatory Affairs |
| Cecilia Hofvander | Vice President of Investor Relations |
| Martin Welschof | President & Chief Executive Officer |
Poll Results
No votes yet today — be the first to share your view!
About BioInvent International AB (publ) (OTC:BOVNF) Stock
BioInvent International AB (publ) is a clinical-stage biotechnology company primarily focused on identifying, exploring, and engineering immunomodulatory antibodies to combat various forms of cancer. The company's activities extend globally, reaching markets in Sweden, across Europe, the United States, Japan, and other international regions. Its leading investigational compound is BI-1206, which is being developed to address both non-Hodgkin lymphoma and a range of solid tumors. Beyond this flagship program, BioInvent is advancing a diverse pipeline of therapeutic candidates. These include agents designed to target tumor-associated myeloid cells and cancer-associated regulatory T cells, which play a vital role in regulating the immune system. The company's portfolio also features BT-001 fo ... r solid tumor indications, as well as BI-1808 and BI-1910 – both anti-TNFR2 antibodies specifically intended for the treatment of solid tumors and cutaneous T-cell lymphoma. To further its development initiatives, BioInvent has established several key collaborations. It maintains a strategic alliance with Pfizer Inc. for the development of antibodies targeting tumor-associated myeloid cells. The company also collaborates with Transgene to jointly create innovative multi-functional oncolytic viruses aimed at solid tumors. Additionally, a collaboration and supply agreement with Merck facilitates the clinical advancement of BI-1808. Founded in 1996, BioInvent International AB (publ) maintains its headquarters in Lund, Sweden.
2026-06-01 21:04:05
BioInvent International AB (publ) (BOVNF) Discusses Ovarian Cancer Treatment Landscape and TNFR2-Targeted Therapies in Solid Tumors Transcript
2026-05-20 05:50:00
LUND, SE / ACCESS Newswire / May 20, 2026 / BioInvent International AB ("BioInvent") (Nasdaq Stockholm:BINV), a leader in the discovery of novel immune‑modulatory antibodies, today announced that it will host a virtual key opinion leader (KOL) event on Wednesday, May 27, 2026 at 8:00 AM EDT / 2:00 PM CEST featuring Dmitriy Zamarin MD, PhD (Tisch Cancer Center, Icahn School of Medicine at Mount Sinai), who will join company management to discuss the unmet need and current treatment landscape for ovarian cancer. To register, click here.
Frequently Asked Questions
-
What is the current BioInvent International AB (publ) (BOVNF) stock price?
-
BioInvent International AB (publ)(OTC:BOVNF) stock price is $3.2886 in the last trading session. During the trading session, BOVNF stock reached the peak price of $4.7 while $3.2886 was the lowest point it dropped to. The percentage change in BOVNF stock occurred in the recent session was 0.0% while the dollar amount for the price change in BOVNF stock was $0.
-
BOVNF's industry and sector of operation?
-
The OTC listed BOVNF is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of BOVNF?
-
Ingrid Teige | Head of Preclinical Research
Kristoffer Rudenholm Hansson | Senior Vice President of Technical Operations
Sylvie Ryckebusch | Chief Business Officer
Andres McAllister | Chief Medical Officer
Stefan Ericsson | Chief Financial Officer -
How many employees does BOVNF have?
-
Number of BOVNF employees currently stands at 109. BOVNF operates from The Gamma Building, Lund, SN 223 70, SE.
-
Link for BOVNF official website?
-
Official Website of BOVNF is: https://www.bioinvent.com
-
How do I contact BOVNF?
-
BOVNF could be contacted at phone #46 4 62 86 85 50 and can also be accessed through its website. BOVNF operates from The Gamma Building, Lund, SN 223 70, SE.
-
How many shares of BOVNF are traded daily?
-
The average number of BOVNF shares traded daily for last 3 months was 777.
-
What is the market cap of BOVNF currently?
-
The market value of BOVNF currently stands at $216.4M with its latest stock price at $3.2886